Multiple Endocrine Neoplasia Syndromes

Surgical Clinics of North America

Volumn 88, Issue 4, 2008, Pages 863-895

  Callender, Glenda G ^a   Rich, Thereasa A ^a   Perrier, Nancy D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN RET; VON HIPPEL LINDAU PROTEIN;

CARNEY COMPLEX; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COWDEN SYNDROME; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; GARDNER SYNDROME; GASTRINOMA; GENE; GENE MUTATION; GLUCAGONOMA; HUMAN; HYPERPARATHYROIDISM; HYPOPHYSIS TUMOR; INSULINOMA; MEN1 GENE; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS RESECTION; PANCREAS TUMOR; PARAGANGLIOMA; PARATHYROID TUMOR; PARATHYROIDECTOMY; PHEOCHROMOCYTOMA; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; REVIEW; SIPPLE SYNDROME; SOMATOSTATINOMA; THYMECTOMY; THYROID MEDULLARY CARCINOMA; THYROID TUMOR; VIPOMA; VON HIPPEL LINDAU DISEASE; ZOLLINGER ELLISON SYNDROME;

ENDOCRINE SURGICAL PROCEDURES; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA; RISK ASSESSMENT;

EID: 47849089705     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2008.05.001     Document Type: Review

References (110)

1. Agarwal S.K., Lee Burns A., Sukhodolets K.E., et al. Molecular pathology of the MEN1 gene. Ann N Y Acad Sci 1014 (2004) 189-198
2. DeLellis R.A., Lloyd R.V., Heitz P.U., et al. Pathology and genetics: Tumours of the endocrine organs. In: Kleihues P., and Sobin L.H. (Eds). World Health Organization Classification of Tumours (2004), IARC Press, Lyon (France) 10:257
3. Bassett J.H., Forbes S.A., Pannett A.A., et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 62 2 (1998) 232-244
4. Stratakis C.A., Schussheim D.H., Freedman S.M., et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 85 12 (2000) 4776-4780
5. Trump D., Farren B., Wooding C., et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 89 9 (1996) 653-669
6. Chandrasekharappa S.C., and Teh B.T. Clinical and molecular aspects of multiple endocrine neoplasia type 1. Front Horm Res 28 (2001) 50-80
7. Marx S. Multiple endocrine neoplasia type 1. In: Scriber C., Sly W., and Childs B. (Eds). The metabolic and molecular basis of inherited disease, 8 (2001), McGraw-Hill Professional, New York 943-966
8. Hall W.A., Luciano M.G., Doppman J.L., et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 120 10 (1994) 817-820
9. Hai N., Aoki N., Shimatsu A., et al. Clinical features of multiple endocrine neoplasia type 1 (MEN1) phenocopy without germline MEN1 gene mutations: analysis of 20 Japanese sporadic cases with MEN1. Clin Endocrinol (Oxf) 52 4 (2000) 509-518
10. Brandi M.L., Gagel R.F., Angeli A., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86 12 (2001) 5658-5671
11. Lairmore T.C., Piersall L.D., DeBenedetti M.K., et al. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). Ann Surg 239 5 (2004) 637-645 [discussion: 645-37]
12. Clark O, Ajani J, Benson A. Neuroendocrine tumors, in NCCN oncology practice guidelines v.1.2007. Available at: www.nccn.org. Last accessed February, 2008.
13. Hellman P., Skogseid B., Oberg K., et al. Primary and reoperative parathyroid operations in hyperparathyroidism of multiple endocrine neoplasia type 1. Surgery 124 6 (1998) 993-999
14. Elaraj D.M., Skarulis M.C., Libutti S.K., et al. Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery 134 6 (2003) 858-864
15. Kivlen M.H., Bartlett D.L., Libutti S.K., et al. Reoperation for hyperparathyroidism in multiple endocrine neoplasia type 1. Surgery 130 6 (2001) 991-998
16. Lambert L.A., Shapiro S.E., Lee J.E., et al. Surgical treatment of hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Arch Surg 140 4 (2005) 374-382
17. Carty S.E., Helm A.K., Amico J.A., et al. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery 124 6 (1998) 1106-1113
18. Verges B., Boureille F., Goudet P., et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 87 2 (2002) 457-465
19. Majewski J.T., and Wilson S.D. The MEA-I syndrome: an all or none phenomenon?. Surgery 86 3 (1979) 475-484
20. Doherty G.M., Olson J.A., Frisella M.M., et al. Lethality of multiple endocrine neoplasia type I. World J Surg 22 6 (1998) 581-586
21. Gibril F., Schumann M., Pace A., et al. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 83 1 (2004) 43-83
22. Pipeleers-Marichal M., Somers G., Willems G., et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med 322 11 (1990) 723-727
23. Norton J.A., Fraker D.L., Alexander H.R., et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 341 9 (1999) 635-644
24. Brandi M.L., Marx S.J., Aurbach G.D., et al. Familial multiple endocrine neoplasia type I: a new look at pathophysiology. Endocr Rev 8 4 (1987) 391-405
25. Norton J.A., Cornelius M.J., Doppman J.L., et al. Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study. Surgery 102 6 (1987) 958-966
26. Skogseid B., Oberg K., Eriksson B., et al. Surgery for asymptomatic pancreatic lesion in multiple endocrine neoplasia type I. World J Surg 20 7 (1996) 872-876
27. Thompson N.W. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 243 6 (1998) 495-500
28. Bartsch D.K., Langer P., Wild A., et al. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance?. Surgery 128 6 (2000) 958-966
29. Lairmore T.C., Chen V.Y., DeBenedetti M.K., et al. Duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 231 6 (2000) 909-918
30. Norton J.A., Doppman J.L., and Jensen R.T. Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study. Ann Surg 215 1 (1992) 8-18
31. Jensen R.T. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 243 6 (1998) 477-488
32. Norton J.A., Alexander H.R., Fraker D.L., et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 234 4 (2001) 495-505
33. Demeure M.J., Klonoff D.C., Karam J.H., et al. Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach. Surgery 110 6 (1991) 998-1004
34. Kouvaraki M., Shapiro S., Lee J., et al. Multiple endocrine neoplasia type 1. In: Von Hoff D., Evans D., and Rh H. (Eds). Pancreatic cancer (2005), Jones and Bartlett Publishers, Sudbury (MA) 631-654
35. Thakker R.V. Multiple endocrine neoplasia type 1. Endocrinol Metab Clin North Am 29 3 (2000) 541-567
36. Mignon M., Ruszniewski P., Podevin P., et al. Current approach to the management of gastrinoma and insulinoma in adults with multiple endocrine neoplasia type I. World J Surg 17 4 (1993) 489-497
37. Kouvaraki M., Perrier N., Rich T., et al. The surgical treatment of MEN-1. In: Pollock R., Curley S., and Ross M. (Eds). Advanced therapy in surgical oncology (2008), BC Decker Inc., Hamilton (ON) 449-464
38. Teh B.T., Zedenius J., Kytola S., et al. Thymic carcinoids in multiple endocrine neoplasia type 1. Ann Surg 228 1 (1998) 99-105
39. Waldmann J., Bartsch D.K., Kann P.H., et al. Adrenal involvement in multiple endocrine neoplasia type 1: results of 7 years prospective screening. Langenbecks Arch Surg 392 4 (2007) 437-443
40. Nord B., Larsson C., Wong F.K., et al. Sporadic follicular thyroid tumors show loss of a 200-kb region in 11q13 without evidence for mutations in the MEN1 gene. Genes Chromosomes Cancer 26 1 (1999) 35-39
41. Darling T.N., Skarulis M.C., Steinberg S.M., et al. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol 133 7 (1997) 853-857
42. Asgharian B., Turner M.L., Gibril F., et al. Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. J Clin Endocrinol Metab 89 11 (2004) 5328-5336
43. McKeeby J.L., Li X., Zhuang Z., et al. Multiple leiomyomas of the esophagus, lung, and uterus in multiple endocrine neoplasia type 1. Am J Pathol 159 3 (2001) 1121-1127
44. Vortmeyer A.O., Lubensky I.A., Skarulis M., et al. Multiple endocrine neoplasia type 1: atypical presentation, clinical course, and genetic analysis of multiple tumors. Mod Pathol 12 9 (1999) 919-924
45. Asgharian B., Chen Y.J., Patronas N.J., et al. Meningiomas may be a component tumor of multiple endocrine neoplasia type 1. Clin Cancer Res 10 3 (2004) 869-880
46. Calender A., Giraud S., Porchet N., et al. Clinicogenetic study of MEN1: recent physiopathological data and clinical applications. Study Group of Multiple Endocrine Neoplasia (GENEM). Ann Endocrinol (Paris) 59 6 (1998) 444-451
47. Santoro M., Carlomagno F., Melillo R.M., et al. Dysfunction of the RET receptor in human cancer. Cell Mol Life Sci 61 23 (2004) 2954-2964
48. Dvorakova S., Vaclavikova E., Duskova J., et al. Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg. J Endocrinol Invest 28 10 (2005) 905-909
49. Da Silva A.M., Maciel R.M., Da Silva M.R., et al. A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab 88 11 (2003) 5438-5443
50. Eng C., Clayton D., Schuffenecker I., et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276 19 (1996) 1575-1579
51. Lips C.J., Landsvater R.M., Hoppener J.W., et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 331 13 (1994) 828-835
52. Machens A., Niccoli-Sire P., Hoegel J., et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349 16 (2003) 1517-1525
53. O'Riordain D.S., O'Brien T., Weaver A.L., et al. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 116 6 (1994) 1017-1023
54. Ponder B.A., Ponder M.A., Coffey R., et al. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1 8582 (1988) 397-401
55. Schuffenecker I., Billaud M., Calender A., et al. RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum Mol Genet 3 11 (1994) 1939-1943
56. Mulligan L.M., Eng C., Healey C.S., et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 6 1 (1994) 70-74
57. Berndt I., Reuter M., Saller B., et al. A new hot spot for mutations in the RET protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83 3 (1998) 770-774
58. Mulligan L.M., Eng C., Attie T., et al. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet 3 12 (1994) 2163-2167
59. Schimke R.N., Hartmann W.H., Prout T.E., et al. Syndrome of bilateral pheochromocytoma, medullary thyroid carcinoma and multiple neuromas. A possible regulatory defect in the differentiation of chromaffin tissue. N Engl J Med 279 1 (1968) 1-7
60. Wray C.J., Rich T.A., Waguespack S.G., et al. Failure to recognize multiple endocrine neoplasia 2B: more common than we think?. Ann Surg Oncol 15 1 (2008) 293-301
61. Mulligan L.M., Marsh D.J., Robinson B.G., et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 238 4 (1995) 343-346
62. Gimm O., Marsh D.J., Andrew S.D., et al. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 82 11 (1997) 3902-3904
63. Fitze G., Schierz M., Bredow J., et al. Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations. Ann Surg 236 5 (2002) 570-575
64. Shannon K.E., Gimm O., Hinze R., et al. Germline V804M mutation in the RET proto-oncogene in two apparently sporadic cases of MTC presenting in the seventh decade of life. J Endocr Genet 1 1 (1999) 39-45
65. Gimm O., Niederle B.E., Weber T., et al. RET proto-oncogene mutations affecting codon 790/791: a mild form of multiple endocrine neoplasia type 2A syndrome?. Surgery 132 6 (2002) 952-959 [discussion: 959]
66. Gimm O., Ukkat J., Niederle B.E., et al. Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J Surg 28 12 (2004) 1312-1316
67. Hansen H.S., Torring H., Godballe C., et al. Is thyroidectomy necessary in RET mutations carriers of the familial medullary thyroid carcinoma syndrome?. Cancer 89 4 (2000) 863-867
68. Brauckhoff M., Gimm O., Hinze R., et al. Papillary thyroid carcinoma in patients with RET proto-oncogene germline mutation. Thyroid 12 7 (2002) 557-561
69. Elisei R., Romei C., Cosci B., et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 92 12 (2007) 4725-4729
70. Machens A., Ukkat J., Brauckhoff M., et al. Advances in the management of hereditary medullary thyroid cancer. J Intern Med 257 1 (2005) 50-59
71. Block M.A., Jackson C.E., Greenawald K.A., et al. Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Treatment implications. Arch Surg 115 2 (1980) 142-148
72. Cohen M.S., and Moley J.F. Surgical treatment of medullary thyroid carcinoma. J Intern Med 253 6 (2003) 616-626
73. Robbins J., Merino M.J., Boice Jr. J.D., et al. Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med 115 2 (1991) 133-147
74. Kouvaraki M., Perrier N., Shapiro S., et al. Surgical treatment of multiple endocrine neoplasia type 2 (MEN-2). In: Pollock R., Curley S., Ross M., et al. (Eds). Advanced therapy in surgical oncology (2008), BC Decker Inc., Hamilton (ON) 465-473
75. Lenders J.W., Pacak K., Walther M.M., et al. Biochemical diagnosis of pheochromocytoma: Which test is best?. JAMA 287 11 (2002) 1427-1434
76. Sawka A.M., Jaeschke R., Singh R.J., et al. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 88 2 (2003) 553-558
77. Bryant J., Farmer J., Kessler L.J., et al. Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst 95 16 (2003) 1196-1204
78. Inabnet W.B., Caragliano P., and Pertsemlidis D. Pheochromocytoma: inherited associations, bilaterality, and cortex preservation. Surgery 128 6 (2000) 1007-1011
79. Yip L., Lee J.E., Shapiro S.E., et al. Surgical management of hereditary pheochromocytoma. J Am Coll Surg 198 4 (2004) 525-534
80. Heath III H., Hodgson S.F., and Kennedy M.A. Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med 302 4 (1980) 189-193
81. Tham E., Grandell U., Lindgren E., et al. Clinical testing for mutations in the MEN1 gene in Sweden: a report on 200 unrelated cases. J Clin Endocrinol Metab 92 9 (2007) 3389-3395
82. Ellard S., Hattersley A.T., Brewer C.M., et al. Detection of an MEN1 gene mutation depends on clinical features and supports current referral criteria for diagnostic molecular genetic testing. Clin Endocrinol (Oxf) 62 2 (2005) 169-175
83. Cardinal J.W., Bergman L., Hayward N., et al. A report of a national mutation testing service for the MEN1 gene: clinical presentations and implications for mutation testing. J Med Genet 42 1 (2005) 69-74
84. Warner J., Epstein M., Sweet A., et al. Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. J Med Genet 41 3 (2004) 155-160
85. Cetani F., Pardi E., Ambrogini E., et al. Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management. Clin Endocrinol (Oxf) 64 2 (2006) 146-152
86. Warner J.V., Nyholt D.R., Busfield F., et al. Familial isolated hyperparathyroidism is linked to a 1.7 Mb region on chromosome 2p13.3-14. J Med Genet 43 3 (2006) e12
87. Baysal B.E., Ferrell R.E., Willett-Brozick J.E., et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287 5454 (2000) 848-851
88. Niemann S., and Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 26 3 (2000) 268-270
89. Astuti D., Latif F., Dallol A., et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69 1 (2001) 49-54
90. Neumann H.P., Bausch B., McWhinney S.R., et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346 19 (2002) 1459-1466
91. Eisenhofer G., Walther M.M., Huynh T.T., et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 86 5 (2001) 1999-2008
92. Hull M.T., Roth L.M., Glover J.L., et al. Metastatic carotid body paraganglioma in von Hippel-Lindau disease. An electron microscopic study. Arch Pathol Lab Med 106 5 (1982) 235-239
93. Walther M.M., and Linehan W.M. Von Hippel-Lindau disease and pheochromocytoma. JAMA 275 11 (1996) 839-840
94. Stolle C., Glenn G., Zbar B., et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 12 6 (1998) 417-423
95. Gimenez-Roqueplo A.P., Lehnert H., Mannelli M., et al. Phaeochromocytoma, new genes and screening strategies. Clin Endocrinol (Oxf) 65 6 (2006) 699-705
96. Brouwers F.M., Eisenhofer G., Tao J.J., et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab 91 11 (2006) 4505-4509
97. Neumann H.P., Pawlu C., Peczkowska M., et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292 8 (2004) 943-951
98. Benn D.E., Gimenez-Roqueplo A.P., Reilly J.R., et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 91 3 (2006) 827-836
99. Schiavi F., Boedeker C.C., Bausch B., et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 294 16 (2005) 2057-2063
100. Timmers H.J., Kozupa A., Eisenhofer G., et al. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 92 3 (2007) 779-786
101. Baysal B.E. Genomic imprinting and environment in hereditary paraganglioma. Am J Med Genet C Semin Med Genet 129 1 (2004) 85-90
102. Gutmann D.H., Aylsworth A., Carey J.C., et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278 1 (1997) 51-57
103. Boedeker C.C., Neumann H.P., Maier W., et al. Malignant head and neck paragangliomas in SDHB mutation carriers. Otolaryngol Head Neck Surg 137 1 (2007) 126-129
104. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 37 11 (2000) 828-830
105. Perrier N.D., van Heerden J.A., Goellner J.R., et al. Thyroid cancer in patients with familial adenomatous polyposis. World J Surg 22 7 (1998) 738-742 [discussion: 743]
106. Carney J.A., Gordon H., Carpenter P.C., et al. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 64 4 (1985) 270-283
107. Canzian F., Amati P., Harach H.R., et al. A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet 63 6 (1998) 1743-1748
108. McKay J.D., Lesueur F., Jonard L., et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet 69 2 (2001) 440-446
109. Malchoff C.D., Sarfarazi M., Tendler B., et al. Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab 85 5 (2000) 1758-1764
110. Charkes N.D. On the prevalence of familial nonmedullary thyroid cancer. Thyroid 8 9 (1998) 857-858